Recommendations for HER 2 assessment in breast cancer

Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

[1]  H. Harputluoglu,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO) , 2014, Journal of chemotherapy.

[2]  R. Parshad,et al.  Assessment of Her‐2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine‐needle aspiration cytology smears: Experience from a tertiary care centre in India , 2014, Diagnostic cytopathology.

[3]  I. Ellis,et al.  The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation , 2014, Journal of Clinical Pathology.

[4]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[5]  Mitch Dowsett,et al.  HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity , 2014, Modern Pathology.

[6]  G. Viale,et al.  Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. , 2013, Breast.

[7]  L. Tafra,et al.  Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? , 2013, Journal of the American College of Surgeons.

[8]  I. Ellis,et al.  Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast , 2012, Histopathology.

[9]  Zhao-xiang Gu,et al.  Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis , 2012, Breast Cancer Research and Treatment.

[10]  G. MacGrogan,et al.  Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH) , 2012, Modern Pathology.

[11]  R. Gelber,et al.  Lapatinib with trastuzumab for HER 2-positive early breast cancer ( NeoALTTO ) : a randomised , open-label , multicentre , phase 3 trial , 2012 .

[12]  R. Gelber,et al.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.

[13]  E. Perez,et al.  HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[17]  M. Dowsett,et al.  Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  N. Sneige,et al.  Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. , 2009, Archives of pathology & laboratory medicine.

[19]  G. Sauter,et al.  HER-2/neu analysis in breast cancer bone metastases , 2009, Journal of Clinical Pathology.

[20]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Gnant,et al.  Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer , 2004, Wiener Klinische Wochenschrift.

[22]  H. Gómez,et al.  Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Ellis,et al.  HER2 testing in the UK: further update to recommendations , 2008, Journal of Clinical Pathology.

[24]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Winther,et al.  EXCESSIVE SECTION DRYING OF BREAST CANCER TISSUE PRIOR TO DEPARAFFINISATION AND ANTIGEN RETRIEVAL CAUSES A LOSS IN HER2- IMMUNO-REACTIVITY , 2008 .

[26]  L. Huo.  HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .

[27]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[28]  B. Ljung,et al.  JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations , 2006 .

[29]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[30]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[31]  M. Risio,et al.  HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. , 2005, Oncology reports.

[32]  I. Ellis,et al.  Best Practice No 176 , 2004, Journal of Clinical Pathology.

[33]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Fletcher,et al.  HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.

[35]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.